FDA examines potential risks of drugs including Effient, Multaq

06/30/2010 | Reuters

The FDA is investigating potential side effects of several treatments, including Eli Lilly and Co.'s blood thinner Effient and Sanofi-Aventis' heart drug Multaq. The agency said it is looking at cases of thrombotic thrombocytopenic purpura and congestive heart failure in patients treated with Effient and Multaq, respectively.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC